On January 10, 2019 Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) reported that it will hold an investor conference call on Wednesday, January 16th, at 4:00 p.m. to update investors on the previously announced and pending acquisitions that offer significant value to the Generex parent company (Press release, Generex, JAN 10, 2019, View Source [SID1234532615]). Joseph Moscato, Generex President & Chief Executive Officer, will discuss the company’s financing plans related to the acquisitions, as well as the strategic focus of Generex for 2019 and beyond. Additionally, Mr. Moscato will provide guidance on the recent merger of Antigen Express into the newly-formed NuGenerex Immuno-oncology, and the proposed spin-out of the company as an independent, public company with a new direction and strategic focus to advance the Ii-Key technology for the immunotherapy of cancer, which includes plans for a rights offering and stock dividend for Generex shareholders in NuGenerex Immuno-Oncology. Further, Mr. Moscato will discuss plans to up-list Generex to a major stock exchange.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mr. Moscato stated, "We have worked diligently over the last several years to transform Generex into an integrated healthcare holding company. In the last two years, we have completed a complex reorganization plan, and we continue to execute on the strategic acquisition of several exciting companies with revenues, products, and new technologies.
"We are in the early stages of our plan that has begun with acquisitions of an MSO network of physicians and surgeons, pharmacies, a laboratory, a surgical supply business, a manufacturer of surgical implants, and two regenerative medicine companies, Regentys and Olaregen. These and future acquisitions will enable Generex to grow through generating significant product and service revenues, while creating exponential value for our shareholders through development of our deep pipeline of clinical-stage assets. I look forward to addressing my fellow Generex shareholders to provide details about recent and pending acquisitions, our growth strategies for NuGenerex Distribution Solutions, and the launch of Generex’s first commercial product Excellagen. I will also discuss the strategy to spin out NuGenerex Immuno-Oncology as an independent public company, with an update on the plan for up-listing Generex."
Dial-in instructions for the investor conference call will be announced on Monday, January 14, 2019.